RAYASAL- salicylic acid 5.9% cream

RayaSal by

Drug Labeling and Warnings

RayaSal by is a Prescription medication manufactured, distributed, or labeled by Raya Pharmaceuticals LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

RayaSal

salicylic acid, 5.9% Cream

Rx Only

For Topical Dermatological Use Only, not for ophthalmic, oral, or intravaginal use.

DESCRIPTION

RAYASAL is applied topically and used to remove excessive keratin in hyperkeratotic skin disorders. Each gram of RAYASAL contains salicylic acid 5.9% as the active ingredient and the following inactive ingredients: cetyl alcohol, disodium EDTA, emulsifying wax, glyceryl stearate SE, jojoba oil, PEG-100 stearate, phenoxyethanol, propylene glycol, purified water, sodium hydroxide, stearic acid, stearyl alcohol, tocopheryl acetate, white petrolatum, xanthan gum.

CLINICAL PHARMACOLOGY

Salicylic acid has been shown to produce desquamation of the horny layer of skin while not affecting qualitative or quantitative changes in the structure of the viable epidermis 1,2. The mechanism of action has been attributed to the dissolution of intercellular cement substances 3. In a study of the percutaneous absorption of salicylic acid 6% in four patients with extensive active psoriasis, Taylor and Halprin 4showed that peak serum salicylate levels never exceeded 5 mg/100 ml even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with higher serum levels (30 to 40 mg/100 ml). Peak serum levels occurred within 5 hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with common extracellular space. (See PRECAUTIONS).

The primary metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%), and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space. Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs. By similar competitive mechanisms, other drugs can influence salicylate serum levels. (See PRECAUTIONS).

CONTRAINDICATIONS

RAYASAL should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients.

INDICATIONS & USAGE

For dermatologic Use

RAYASAL is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis.

For Podiatric Use

RAYASAL is a topical aid in removing excessive keratin on dorsal and plantar hyperkeratotic lesions.

WARNINGS

RAYASAL is for external use only. It is not for ophthalmic, oral, anal, or intravaginal use. Contact with eyes, lips, broken or inflamed skin, and mucous membranes should be avoided. RAYASAL should not be used by persons who have a known hypersensitivity to salicylic acid or other listed ingredients. Prolonged use over large areas, especially in children and those patients with significant renal or hepatic impairment, could result in salicylism. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or hepatic impairment, the area to be treated should be limited, and the patient should be monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnoea, diarrhea, psychic disturbances.

In the event of salicylic acid toxicity, RAYASAL should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Considering the potential risk of developing Reye's syndrome, salicylate products should not be administered to children or teenagers with varicella or influenza, unless directed by a physician.

PRECAUTIONS

RAYASAL should be used only as directed by a physician and should not be used to treat any condition other than that for which it is prescribed. RAYASAL should not be used on any skin area where inflammation or exudation is present as increased absorption may occur. If redness or irritation occurs, discontinue use and consult with prescribing physician.

DRUG INTERACTIONS

The following interactions are from a published review 5and include reports concerning oral and topical salicylate administration. The relationship of these interactions to the use of SALICYLIC ACID is not known.

A. Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:
Drug	Description of Interaction
Tolbutamide; Sulfonylureas	Hypoglycemia potentiated
Methotrexate	Decreases tubular reabsorption; clinical toxicity from methotrexate can result
Oral Anticoagulants	Increased bleeding
B. Drugs changing salicylate levels by altering renal tubular reabsorption:
Drug	Description of Interaction
Corticosteroids	Decreases plasma salicylate level; tapering doses of steroids may promote salicylism
Ammonium Sulfate	Increases plasma salicylate level
C. Drugs with complicated interactions with salicylates:
Drug	Description of Interaction
Heparin	Salicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients
Pyrazinamide	Inhibits pyrazinamide-induced hyperuricemia
Uricosuric Agents	Effect of probenecid, sulfinpyrazone, and phenylbutazone inhibited
D. The following alterations of laboratory tests have been reported during salicylate therapy:6
Laboratory Tests	Effect of Salicylates
Thyroid Function	Decreased PBI; increased T uptake
Urinary Sugar	False negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g qd)
5 Hydroxyindole Acetic Acid	False negative with fluorometric test
Acetone, Ketone Bodies	False positive FeCl in Gerhardt reaction; red color persists with boiling
17-OH corticosteroids	False reduced values with >4.8 g qd salicylate
Vanilmandelic Acid	False reduced values
Uric Acid	May increase or decrease depending on the dose
Prothrombin	Decreased levels; slightly increased prothrombin time

PREGNANCY

Pregnancy (Category C)

Salicylic acid is teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent four times the Maximum daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. RAYASAL should be used during pregnancy only if the potential benefit justifies the risk to the fetus.

Nursing Mothers

It is unknown whether topically applied salicylic acid is excreted in human milk. Since many drugs are excreted in human milk, caution should be exercised by physicians when administering RAYASAL to nursing mothers and nursing mothers should certainly not apply RAYASAL to the chest area or any other part of the body with which the nursing child's mouth is likely to come in contact. Because of the potential for serious adverse reactions in nursing infants from the mother's use of RAYASAL, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No data are available concerning the potential carcinogenic or reproductive effects of RAYASAL. It has been shown to lack mutagenic potential in the Ames Salmonella test.

KEEP THIS AND ALL OTHER MEDICATIONS OUT OF THE REACH OF CHILDREN.

ADVERSE REACTIONS

Transient stinging, burning, itching or irritation is possible. Peeling of the skin may increase as the salicylic acid works to loosen excess keratin. If excessive burning, stinging or peeling occurs, discontinue use and consult your physician.

DOSAGE & ADMINISTRATION

Clean and dry affected area of skin, Then apply RayaSal topically over the affected skin twice daily, or as directed by healthcare provider. Rub in until completely fade.

The preferable method of use is to apply RAYASAL Cream thoroughly to the affected area and occlude the area at night. Preferably, the skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning, and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once the clearing is apparent, the occasional use of RAYASAL Cream will usually maintain the remission. In those areas where occlusion is difficult or impossible, the application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect. Unless hands are being treated, hands should be rinsed thoroughly after application.

HOW SUPPLIED

RAYASAL Salicylic Acid 5.9% Gel is supplied in a 95-gram AIRLESS pump bearing the NDC Number 382098-009-95

Store at a controlled room temperature of 15° - 30°C (59° - 86°F). [See USP “Controlled Room Temperature”]

REFERENCES

1. Davies M, Marks R: Br J Dermatol 95: 187-192, 1976.
2. Mars R, Davies M, Cattel A: J Invest Dermatol 64: 283, 1975.
3. Huber C, Christophers E: Arch Derm Res 257: 293-297, 1977.
4. Taylor JR, Halprin KM: Arch Dermatol 111: 740-743, 1975.
5. Goldsmith LA: Int J Dermatol 18: 32-36.
6. Wilson JG, Ritter EJ, Scott WJ, Fradlein R: Tox Appl Pharmacol 41: 67-78, 1977.

All prescription substitutions using this product shall be made subject to state and federal statutes as applicable. NOTE: This is not an Orange Book product and has not been subjected to FDA therapeutic equivalency or another equivalency testing. No representation is made as to the generic status or bioequivalency. Each person recommending a prescription substitution using this product shall make such recommendations based on each such person’s professional opinion and knowledge upon evaluating the active ingredients, excipients, inactive ingredients, and chemical formulation information provided herein.

MANUFACTURED FOR RAYA Pharmaceuticals, LLC Kingsland, GA, 31548 1-800-467-1205 REV 1/22

PRINCIPAL DISPLAY PANEL

NDC: 382098-009-95

RayaSal

salicylic acid 5.9%

Topical Cream

For Topical Dermatological Use Only, not for ophthalmic, oral, or intravaginal use.

RX Only

NET WT. 3.35 OZ (95 g)

MANUFACTURED FOR
RAYA Pharmaceuticals, LLC
Kingsland, GA, 31548
1-800-467-1205
REV 1/22

INGREDIENTS AND APPEARANCE

RAYASAL 
salicylic acid 5.9% cream

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 82098-009
Route of Administration	TOPICAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
SALICYLIC ACID (UNII: O414PZ4LPZ) (SALICYLIC ACID - UNII:O414PZ4LPZ)	SALICYLIC ACID	59 mg  in 1 g

Inactive Ingredients
Ingredient Name	Strength
PEG-100 STEARATE (UNII: YD01N1999R)
.ALPHA.-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0)
WHITE PETROLATUM (UNII: B6E5W8RQJ4)
CETYL ALCOHOL (UNII: 936JST6JCN)
EDETATE CALCIUM DISODIUM (UNII: 25IH6R4SGF)
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
WATER (UNII: 059QF0KO0R)
JOJOBA OIL (UNII: 724GKU717M)
XANTHAN GUM (UNII: TTV12P4NEE)
PHENOXYETHANOL (UNII: HIE492ZZ3T)
SODIUM HYDROXIDE (UNII: 55X04QC32I)
STEARIC ACID (UNII: 4ELV7Z65AP)
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)
GLYCERYL STEARATE SE (UNII: FCZ5MH785I)
WHITE WAX (UNII: 7G1J5DA97F)

Product Characteristics
Color	white	Score
Shape		Size
Flavor		Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 82098-009-95	1 in 1 CARTON	10/17/2022
1		95 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		10/17/2022

Labeler - Raya Pharmaceuticals LLC (106631637)